In BioMed research international ; h5-index 102.0
In this paper, in-depth research analysis of anti-hepatocellular carcinoma molecular targets for hepatocellular carcinoma diagnosis was conducted using artificial intelligence. Because BRD4 plays an important role in gene transcription for cell cycle regulation and apoptosis, tumor-targeted therapy by inhibiting the expression or function of BRD4 has received increasing attention in the field of antitumor research. Study subjects in small samples were used as the validation set for validating each diagnostic model constructed based on the training set. The diagnostic effect of each model in the validation set is evaluated by calculating the sensitivity, specificity, and compliance rate, and the model with the best and most stable diagnostic value is selected by combining the results of model construction, validation, and evaluation. The total sample was divided into a training set and test set by using a stratified sampling method in the ratio of 7 : 3. Logistic regression, weighted k-nearest neighbor, decision tree, and BP artificial neural network were used in the training set to construct diagnostic models for early-stage liver cancer, respectively, and the optimal parameters of the corresponding models were obtained, and then, the constructed models were validated in the test set. To evaluate the diagnostic efficacy, stability, and generalization ability of the four classification methods more robustly, a 10-fold crossover test was performed for each classification method. BRD4 is an epigenetic regulator that is associated with the upregulation of expression of various oncogenic drivers in tumors. Targeting BRD4 with pharmacological inhibitors has emerged as a novel approach for tumor treatment. However, before we implemented this topic, there were no detailed studies on whether BRD4 could be used for the treatment of HCC, the role of BRD4 in HCC cell proliferation and apoptosis, and the ability of small molecule BRD4 inhibitors to induce apoptosis in hepatocellular carcinoma cells.
Wang Yuan, Wei Chao, Deng Xiangui, Gao Shudi, Chen Jing